Market capitalization | $2.21b |
Enterprise Value | $2.21b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 8.27 |
P/S ratio (TTM) P/S ratio | 8.27 |
P/B ratio (TTM) P/B ratio | 10.79 |
Revenue growth (TTM) Revenue growth | 29.41% |
Revenue (TTM) Revenue | $267.23m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
6 Analysts have issued a Sema4 Holdings Corp - Ordinary Shares - Class A forecast:
6 Analysts have issued a Sema4 Holdings Corp - Ordinary Shares - Class A forecast:
Sep '24 |
+/-
%
|
||
Revenue | 267 267 |
29%
29%
|
|
Gross Profit | 140 140 |
2,934%
2,934%
|
|
EBITDA | -30 -30 |
84%
84%
|
EBIT (Operating Income) EBIT | -54 -54 |
78%
78%
|
Net Profit | -84 -84 |
82%
82%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Sema4 Holdings Corp.is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm through its Centrellis health intelligence platform enables to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in 2016 and is headquartered in Stamford, CT.
Head office | United States |
CEO | Katherine Stueland |
Employees | 1,000 |
Founded | 2015 |
Website | www.genedx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.